Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations
Natalie E. West(Johns Hopkins University), Patrick A. Flume(Medical University of South Carolina), Donald R. VanDevanter(Case Western Reserve University), Jerry A. Nick(National Jewish Health), Christopher H. Goss(University of Washington Medical Center), Raksha Jain(Westmead Institute for Medical Research), George M. Solomon(University of Alabama), Valeria Beckett(Cystic Fibrosis Foundation), Don B. Sanders(Indiana University School of Medicine), Elliott C. Dasenbrook(Cleveland Clinic), Sonya L. Heltshe
Cited by 100
Related Papers
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Dual SMAD Signaling Inhibition Enables Long-Term Expansion of Diverse Epithelial Basal Cells
|Cell stem cell|2016|409
Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections
|American Journal of Respiratory and Critical Care Medicine|2017|393